According to disclosures from the Hong Kong Stock Exchange on September 29, Betta Pharmaceuticals Co.,Ltd. (300558.SZ) has submitted its listing application to the main board of the Hong Kong Stock Exchange, with Morgan Stanley and CITIC Securities serving as joint sponsors. Notably, this marks Betta Pharmaceuticals' third attempt at a Hong Kong listing. Looking back to 2021, the company submitted prospectuses to the Hong Kong Stock Exchange twice, in February and December, but both listing attempts were unsuccessful.
The prospectus reveals that Betta Pharmaceuticals Co.,Ltd. is a pioneer and leader in China's innovative drug R&D industry, having successfully transformed from a biotechnology company focused on innovative drug discovery and development into an industry-leading, profitable biopharmaceutical company. The company has established an integrated platform driven by four synergistic pillars: proprietary R&D, market expansion, strategic cooperation, and ecosystem development. To date, the company has successfully launched eight commercialized products, with several achieving "China's first" breakthroughs. Since its first product launch in 2011, the company has maintained profitability for consecutive years, securing a leading position among China's innovative pharmaceutical companies.
Since its establishment in 2003, the company has consistently focused on developing novel drugs for cancer treatment to address urgent clinical needs in lung cancer and other major cancer areas. On one hand, through a combination of proprietary R&D and strategic partnerships, the company has built a comprehensive drug pipeline covering key lung cancer targets, including epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), helping establish its leading position in innovative targeted lung cancer therapy. On the other hand, the company continues to expand into high-potential therapeutic areas, including breast cancer, kidney cancer, hematology, and ophthalmology.
Following this strategic development path, the company has successfully transformed into a "platform-type pharmaceutical enterprise," constructing a robust and scalable platform that integrates four core pillars: mature commercialization capabilities, comprehensive drug discovery and R&D capabilities, forward-looking business development strategies, and a competitive innovation ecosystem. Leveraging this powerful platform, the company has established a rich drug pipeline and achieved commercialization of eight drugs, including five innovative drugs (icotinib (Conmana®), ensartinib (Benmana®), befotertinib (Saimana®), vorolanib (Fumana®), and terselizumab (Kangmana®)), one biosimilar drug (bevacizumab injection (MIL60/Beantin®)), and two co-marketed products: trastuzumab biosimilar (Anruize®) and recombinant human albumin injection (rice) (Aofomin®).
Through the four-pillar approach of "commercialization × R&D × strategic cooperation × ecosystem," the company continues to expand its R&D pipeline and therapeutic areas through multiple rounds of growth at different stages, including: (i) comprehensive lung cancer pipeline, (ii) pipelines for malignant tumors beyond lung cancer, and (iii) non-oncology disease pipelines, focusing on major disease areas with unmet clinical needs and broad market potential.
Financially, for the years 2022, 2023, 2024, and the six months ended June 30, 2025, Betta Pharmaceuticals Co.,Ltd. achieved revenues of approximately RMB 2.377 billion, RMB 2.456 billion, RMB 2.892 billion, and RMB 1.731 billion, respectively. Annual profits were approximately RMB 125 million, RMB 334 million, RMB 387 million, and RMB 131 million, respectively.